The short version of triple agonist fits in a sentence. The long version — which is the one that helps — is below.
Reviewed 2026-02-02. Anything still debated is marked as such rather than presented as settled.
Pharmacologically, retatrutide acts as a triple agonist at the glucagon-like peptide-1 receptor, the glucose-dependent insulinotropic polypeptide receptor, and the glucagon receptor. Activation of the first two receptors is associated with improved insulin secretion and reduced appetite. The glucagon receptor component is thought to increase energy expenditure, a mechanism that distinguishes this molecule from dual-agonist compounds. Researchers continue to investigate how the three activities interact and whether the combined profile offers advantages that justify additional clinical testing.
Several questions about the compound remain unresolved. The durability of weight reduction after treatment stops, the frequency of gastrointestinal side effects, and the long-term cardiovascular profile are topics of ongoing study. Regulatory submissions and phase 3 trial outcomes have not been fully reported in the public literature. Because most available data come from controlled trials rather than general-population use, conclusions about effectiveness outside study settings are provisional. The distinction between established findings and open questions matters when interpreting early coverage of the drug.
Retatrutide is an investigational peptide studied for obesity and type 2 diabetes. It is a single synthetic molecule designed to activate three metabolic receptors simultaneously. The compound belongs to the incretin mimetic family, a group of peptides that imitate gut hormones involved in appetite and glucose control. Its research code is LY3437943, and it remains under clinical study rather than cleared for routine medical use.
Acting as a triple agonist, the molecule binds the GLP-1, GIP, and glucagon receptors. GLP-1 activity slows gastric emptying and dampens appetite, while GIP signaling contributes to insulin sensitivity and fat metabolism. Glucagon receptor engagement raises energy expenditure and encourages fat breakdown, although it can also elevate blood glucose. Combining three pathways is intended to yield larger weight reduction than single or dual agonists, and researchers continue to examine how the balance among them shapes tolerability.
Clinical studies have reported notable reductions in body weight among participants. Early trials measured safety and explored several dose levels, and later studies tracked body-weight change over months of treatment. Investigators also monitor effects on glycemic markers, liver fat, and blood lipids. Because the compound is still in development, questions about long-term safety, cardiovascular outcomes, and durability after treatment ends remain open.
| Property | Value | Notes |
|---|---|---|
| Molecular class | Synthetic peptide | Contains non-natural residues |
| Receptor targets | GLP-1, GIP, glucagon | Triple agonist profile |
| Route of administration | Subcutaneous injection | In clinical trial settings |
| Development status | Investigational | Not approved in major markets |
| Approximate molecular mass | About 4.7 kDa | Peptide-scale molecule |
Mechanistic proposals link each receptor to a different physiological role. Activation of the glucose-dependent insulinotropic polypeptide and glucagon-like peptide-1 receptors is associated with reduced appetite, slower gastric emptying, and glucose-dependent insulin release. Glucagon receptor signaling, by contrast, is associated with increased energy expenditure and altered lipid handling, though it can also raise blood glucose. The design intent is to balance these contributions so that weight reduction is enhanced without unacceptable glycemic trade-offs. How well that balance holds across individuals is not fully resolved.
Published information places retatrutide in clinical development rather than on the market as an approved therapy. Early-stage and mid-stage trials have examined tolerability and changes in body weight, and larger studies continue to report results over time. Open questions include the durability of effects after treatment stops, the composition of weight lost, and cardiovascular outcomes over long periods. Statements about definitive benefit should therefore be treated as provisional. Regulatory status varies by jurisdiction and changes as applications are reviewed.
Development has progressed from single- and multiple-ascending-dose studies in healthy volunteers into larger randomized trials in adults with obesity, type 2 diabetes, and fatty liver disease. Early reports describe dose-dependent reductions in body weight and improvements in glycemic markers over treatment periods of several months. Whether the glucagon arm adds tolerability cost without added benefit is still debated. Long-term cardiovascular outcomes, effects after treatment stops, and performance in older or comorbid populations are open questions rather than settled findings. Approval status may change, so the current investigational label should be confirmed against regulatory sources.
Retatrutide is an investigational synthetic peptide developed under the code LY3437943, with a backbone derived from glucose-dependent insulinotropic polypeptide. Several non-proteinogenic residues, including alpha-aminoisobutyric acid, appear in that backbone, and a fatty diacid side chain attached through a linker extends circulation time. The molecule carries roughly thirty-nine amino acid units and a total mass near 4.7 kilodaltons. Administration is by subcutaneous injection once weekly. Published work uses both the name retatrutide and the code LY3437943.
==== Congenital abnormalities ==== Cleft lip and palate in combination; cleft lip (cheiloschisis) and cleft palate (palatoschisis), individually. Congenital nasal abnormalities Genetically derived ethnic-nose abnormalities
=== Cargo === In 2025, Hohhot Baita International Airport handled 60,200 tons of cargo and mail, surpassing the 60,000‑ton mark for the first time, an annual increase of 1.8%. In December alone, throughput reached 7,977 tons, setting a new historical record. Over the year, the airport transported 6,181 tons of fresh meat products, accounting for 10% of total cargo volume, while cold‑chain veterinary pharmaceuticals reached 570 tons, a 30% increase from the previous year.
Among college students, the top issues are healthcare reforms, the cost of education, and civil rights. Most do not care about Middle Eastern conflicts and the associated protests on college campuses, but are more interested in lucrative careers after graduation. Among young men, a majority think that both parties hold extreme views, but that the Republican Party is more so than the Democratic Party. Being disappointed at the status quo has been an impetus for them to run for office, taking advantage of the fact that a majority of voters would like to see younger faces in politics. Social media networks have played a crucial role in how members Generation Z form and share their political views. The algorithms of these platforms typically serve contents that reinforce the views of the user and help them mind other like-minded individuals. There is evidence that TikTok has led to the rightward shift of Generation Z. On the other hand, it has also brought Representative Alexandria Ocasio-Cortez to the attention of many Gen-Z women. Compared to older cohorts, Generation Z as a group is more skeptical of the American federal government and less concerned about the possible risks to national security posed by TikTok; many oppose the proposed TikTok ban. As a result, politicians from both major political parties have been trying to appeal to young voters on social networks, including TikTok itself. Generation Z's political views have also been shaped by the way they are taught history.
Anti-cardiolipin antibodies (ACA) are antibodies often directed against cardiolipin and found in several diseases, including syphilis, antiphospholipid syndrome, livedoid vasculitis, vertebrobasilar insufficiency, Behçet's syndrome, idiopathic spontaneous abortion, and systemic lupus erythematosus (SLE). They are a form of anti-mitochondrial antibody. In SLE, anti-DNA antibodies and anti-cardiolipin antibodies may be present individually or together; the two types of antibodies act independently. This is in contrast to rheumatoid arthritis with systemic sclerosis (scleroderma) because anti-cardiolipin antibodies are present in both conditions, and therefore may tie the two conditions together. Anti-cardiolipin antibodies can be classified in two ways:
The goal of protein design is to find a protein sequence that will fold to a target structure. A protein design algorithm must, thus, search all the conformations of each sequence, with respect to the target fold, and rank sequences according to the lowest-energy conformation of each one, as determined by the protein design energy function. Thus, a typical input to the protein design algorithm is the target fold, the sequence space, the structural flexibility, and the energy function, while the output is one or more sequences that are predicted to fold stably to the target structure. The number of candidate protein sequences, however, grows exponentially with the number of protein residues; for example, there are 20100 protein sequences of length 100. Furthermore, even if amino acid side-chain conformations are limited to a few rotamers (see Structural flexibility), this results in an exponential number of conformations for each sequence. Thus, in our 100 residue protein, and assuming that each amino acid has exactly 10 rotamers, a search algorithm that searches this space will have to search over 200100 protein conformations. The most common energy functions can be decomposed into pairwise terms between rotamers and amino acid types, which casts the problem as a combinatorial one, and powerful optimization algorithms can be used to solve it. In those cases, the total energy of each conformation belonging to each sequence can be formulated as a sum of individual and pairwise terms between residue positions.
Sources: en.wikipedia.org
== Pharmacological properties == Oripavine possesses an analgesic potency comparable to morphine; however, it is not clinically useful due to severe toxicity and low therapeutic index. In both mice and rats, toxic doses caused tonic-clonic seizures followed by death, similar to thebaine. Oripavine has a potential for dependence which is significantly greater than that of thebaine but slightly less than that of morphine.
== Distribution and habitat == Euphorbia caducifolia has a rather limited distribution in the Thar Desert in the northwestern part of the Indian subcontinent, on the boundary between India and Pakistan. This is an area of sandy hills and shifting sand dunes, with clumps of thorny vegetation, low trees, grasses and scrub.
=== Hi–Hu === Evelyn Hickmans] (1883–1972). British biochemist, pioneer in treatment of phenylketonuria Archibald Vivian Hill FRS (1886–1977). British protein biophysicist at University College London known primarily for work in muscle biochemistry, but also for the Hill equation, still widely used for quantifying protein cooperativity. Nobel Prize in Physiology or Medicine (1922). Robin Hill FRS (1899–1991). British plant biochemist at the University of Cambridge who demonstrated the Hill reaction of photosynthesis. Frank Hird (1920–2014). Australian agricultural biochemist at the University of Melbourne. Dorothy Hodgkin FRS (1910–1994). British X-ray crystallographer at the University of Oxford, pioneer in protein crystallography. Nobel Prize in Chemistry (1964) Jan-Hendrik S. Hofmeyr (b. 1953). South African biochemist at the University of Stellenbosch active in metabolic control analysis. Kenneth Charles Holmes FRS (1934–2021), British molecular biologist and a pioneer in using synchrotron X-ray radiation Mei Hong (born 1970). Chinese-American biophysical chemist known for development solid-state nuclear magnetic resonance to elucidate the structures and mechanisms of membrane proteins Nick Hoogenraad (active from 1969). Australian biochemist, discoverer of the mechanism of the mitochondrial unfolded protein response, Professor of Biochemistry at La Trobe University (1993–2014). Frederick Gowland Hopkins FRS (President) (1861–1947). British biochemist at Cambridge University who discovered tryptophan and worked on vitamins.
The Kizil Caves are "the earliest representative grottoes in China". The art of the Kizil Caves is thought to have influenced cave art at Dunhuang, in the Mogao Caves, as early as during the Northern Liang dynasty (421–439 CE), and pictorial arts in China thereafter. According to historian Daniel C. Waugh:
Sources: en.wikipedia.org
After Runciter disappears, Jory reveals himself to Chip, telling him that he, not Conley, has now killed off the entire group (including Conley), as he "eats" half-lifers to sustain himself, and that the entire reality they are experiencing is created and maintained by him. Fortunately, Chip is temporarily protected from being consumed through the effect of Ubik, and leaves Jory. As he at last begins to deteriorate again, he meets Ella, who saves him by granting him a certificate for a life-long supply of Ubik, and instructs him to stay half-alive and seek cans of Ubik to further assist Runciter after she herself reincarnates. She states that Jory's family pays the facility to keep his body near other half-lifers for him to consume in order to prolong his own half-life, and that entities like Jory can arise in any collection of half-lifers. Ubik is claimed to have been developed by Ella and several other half-lifers as a defense against Jory. Each chapter is introduced by a commercial advertising Ubik as a different product serving a specific use. The last chapter is introduced by Ubik claiming that it has created and directed the universe, and that its real name is unknown and unspoken. In this short chapter, Runciter, who is in the "living" world mourning the loss of his best employees, discovers coins showing Chip's face, and feels that this is "just the beginning".
The way a drug product is designed and manufactured Its physical and chemical properties Other ingredients it contains The physiologic characteristics of the person taking the drug How the drug is stored
The East Central Conference is a former high school athletic conference in Wisconsin. Originally founded in 1970, it was disbanded in 2001 and remained defunct until its reconstitution in 2015. It lasted for ten seasons before a second dissolution in 2025, and all members in both incarnations belonged to the Wisconsin Interscholastic Athletic Association.
== Research focus == In his 1981 Ph.D. thesis, Youvan found inhibitors (hypermodified nucleosides) of retroviral reverse transcriptase present in ribosomal RNA. His work correctly predicted the secondary structure of the 11 transmembrane helices of the reaction center as confirmed by X-ray crystallography. In 1987 Youvan and E. Bylina constructed the first site-directed mutants of bacterial reaction centers.
=== Treatment ex situ and in situ === Several technologies can remove perchlorate, via treatments ex situ (away from the location) and in situ (at the location). Ex situ treatments include ion exchange using perchlorate-selective or nitrite-specific resins, bioremediation using packed-bed or fluidized-bed bioreactors, and membrane technologies via electrodialysis and reverse osmosis. In ex situ treatment via ion exchange, contaminants are attracted and adhere to the ion exchange resin because such resins and ions of contaminants have opposite charge. As the ion of the contaminant adheres to the resin, another charged ion is expelled into the water being treated, in which then ion is exchanged for the contaminant. Ion exchange technology has advantages of being well-suitable for perchlorate treatment and high volume throughput but has a downside that it does not treat chlorinated solvents. In addition, ex situ technology of liquid phase carbon adsorption is employed, where granular activated carbon (GAC) is used to eliminate low levels of perchlorate and pretreatment may be required in arranging GAC for perchlorate elimination. In situ treatments, such as bioremediation via perchlorate-selective microbes and permeable reactive barrier, are also being used to treat perchlorate. In situ bioremediation has advantages of minimal above-ground infrastructure and its ability to treat chlorinated solvents, perchlorate, nitrate, and RDX simultaneously. However, it has a downside that it may negatively affect secondary water quality.
Sources: en.wikipedia.org
It is designed as a triple agonist acting on the GLP-1, GIP, and glucagon receptors. This combination is intended to influence appetite, insulin secretion, and energy expenditure. Single-receptor and dual-receptor compounds act on a narrower set of targets.
No. It remains investigational, and phase 3 results have not been fully published or reviewed by regulators. Official approval status should be confirmed through regulatory agencies rather than secondary sources.
The added glucagon receptor activity is the main difference in its mechanism. Whether that addition produces meaningful benefits in clinical outcomes is still being studied. Comparisons between compounds rest largely on indirect rather than head-to-head trial data.
It is a synthetic peptide classified as a triple receptor agonist. It engages the GLP-1, GIP, and glucagon receptors at once. It is investigated for metabolic and weight-related conditions rather than approved for general use.